Corcept Therapeutics Q1 EPS $0.25 Beats $0.22 Estimate, Sales $146.81M Beat $140.80M Estimate
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics (NASDAQ:CORT) reported Q1 earnings of $0.25 per share, surpassing the $0.22 estimate, a 78.57% increase from last year. Sales reached $146.81M, beating the $140.80M estimate, marking a 38.95% increase from the previous year.
May 01, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics reported a significant beat on both earnings and sales estimates for Q1, with earnings per share at $0.25 and sales at $146.81M.
The positive earnings and sales beat indicate strong financial health and operational efficiency, likely leading to increased investor confidence and a potential short-term uptick in CORT's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100